Novo Nordisk is planning to open an artificial ... In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery engine to find ...

Photo by News Øresund – Kristoffer Dahl via CC BY 3.0 Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery. 2 min read Get More Than ...

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this pharmaceutical revolution. Medicare price negotiations may tighten ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...

Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 11 unusual trades. Delving into the details, we found 72% of ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this ...